SCHEMBL4876419

SCHEMBL4876419

CC(C)(C)CNC(=O)c1ccc(Br)c(C=O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.57
CNR1 P21554 3/20 0.57
HPGD P15428 2/20 0.42
NAMPT P43490 1/20 0.41
ADORA2A P29274 1/20 0.41
RAB9A P51151 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
DDR1 Q08345 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3895613 0.83 CNR2 (0.49) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL3895618 0.83 CNR2 (0.49) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL3894629 0.81 CNR2 (0.57) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL3890880 0.79 CNR2 (0.53) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL4884688 0.78 CNR2 (0.55) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL4882979 0.76 CNR2 (0.53) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL4876418 0.76 CNR2 (0.53) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL17865785 0.76 ADORA2A (0.59) CNR2CNR1HPGDNAMPTADORA2A
SCHEMBL3893570 0.75 MAPT (0.57) CNR2CNR1HPGDRAB9ANPSR1
SCHEMBL5623628 0.73 CNR2 (1.00) CNR2CNR1RAB9ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051416-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-02-28 US disclosed
US-20080051416-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-02-28 US disclosed
US-20080051416-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-02-28 US disclosed
EP-1805132-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-07-11 EP disclosed
WO-2006110173-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051416-A1 Novel Compounds MAPK1, MAPKAPK2, MAPK6 CNR2 1310/4885CNR1 981/4885HPGD 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.